Trials / Completed

CompletedNCT00128232

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

Safety and Efficacy of Octreotide LAR in Treatment Naïve Acromegalic Patients

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 100 (planned)

Sponsor: Novartis · Industry
Sex: All
Age: 18 Years – 80 Years
Healthy volunteers: —

Summary

Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly. Octreotide LAR is approved for treatment of acromegaly after surgery if the disease is not controlled. This study was aimed to test the safety and efficacy of octreotide LAR in acromegalic patients who did not have any previous treatment for acromegaly.

Conditions

Acromegaly

Interventions

Type	Name	Description
DRUG	Octreotide LAR

Timeline

Start date: 2002-12-01
Primary completion: 2004-08-01
First posted: 2005-08-09
Last updated: 2012-04-30

Source: ClinicalTrials.gov record NCT00128232. Inclusion in this directory is not an endorsement.